A wide range of HER3 membrane expressions was observed in the clinical activity and Patritumab Deruxtecan could be an approach to treat a broad range of drug-resistant tumors due to clinical activity in EGFR-TKI resistant cancers [137]. This evidence concerns the gene ERBB3 and cancer.